| 1 |
16980238 | [Keyrole of endocrinology in the victory against prostate cancer]. | 2006 Sep |
2 |
| 2 |
12536355 | Regulation of gonadotropin secretion: implications for polycystic ovary syndrome. | 2002 Nov |
1 |
| 3 |
11316974 | Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. | 2001 |
1 |
| 4 |
11095431 | Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. | 2000 Nov |
1 |
| 5 |
9761805 | Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. | 1998 Oct 8 |
1 |
| 6 |
8977067 | Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients. | 1996 |
1 |
| 7 |
9170575 | Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer. | 1996 Nov |
1 |
| 8 |
7538237 | A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. | 1995 May |
3 |
| 9 |
8111715 | Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. | 1994 Mar 1 |
1 |
| 10 |
1794008 | Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer. | 1991 Mar |
1 |
| 11 |
2144819 | Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate. | 1990 |
2 |
| 12 |
2193461 | Flutamide: an antiandrogen for advanced prostate cancer. | 1990 Jun |
2 |
| 13 |
2670515 | Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. | 1989 Aug |
1 |
| 14 |
3279409 | Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. | 1988 |
1 |
| 15 |
3283766 | Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer. | 1988 |
1 |
| 16 |
3285484 | Advantages of total androgen blockade in the treatment of advanced prostate cancer. | 1988 Apr |
1 |
| 17 |
3286322 | A pure antiandrogen does not interfere with the LHRH agonist-induced blockade of testicular androgen secretion in the dog. | 1988 Mar |
1 |
| 18 |
3100871 | Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. | 1986 Nov |
2 |
| 19 |
2934579 | Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. | 1985 Nov |
1 |